Macquarie Group
FATE icon

Macquarie Group’s Fate Therapeutics FATE Stock Holding History

Macquarie Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-636
Closed -$40K – 1878
2022
Q3 		$40K Sell
636
-1,155
-64% -$33.4K ﹤0.01% 2007
2022
Q2 		$44K Hold
1,791
– – ﹤0.01% 2084
2022
Q1 		$69K Sell
1,791
-28,392
-94% -$1.1M ﹤0.01% 2042
2021
Q4 		$1.77M Buy
30,183
+737
+3% +$41.8K ﹤0.01% 1411
2021
Q3 		$1.75M Sell
29,446
-33,461
-53% -$2.62M ﹤0.01% 1422
2021
Q2 		$5.46M Sell
62,907
-919
-1% -$74.1K ﹤0.01% 1115
2021
Q1 		$5.26M Sell
63,826
-11,263
-15% -$1.08M 0.01% 895
2020
Q4 		$6.83M Buy
75,089
+6,376
+9% +$396K 0.01% 806
2020
Q3 		$2.75M Sell
68,713
-2,063
-3% -$72K ﹤0.01% 957
2020
Q2 		$2.43M Buy
+70,776
New +$2.11M ﹤0.01% 956
2019
Q1 		– Sell
-700
Closed -$9K – 1775
2018
Q4 		$9K Sell
700
-200
-22% -$2.79K ﹤0.01% 1940
2018
Q3 		$15K Sell
900
-2,400
-73% -$28.4K ﹤0.01% 1943
2018
Q2 		$37K Buy
+3,300
New +$36.4K ﹤0.01% 1991
2018
Q1 		– Sell
-1,800
Closed -$11K – 2229
2017
Q4 		$11K Buy
+1,800
New +$8.03K ﹤0.01% 2249

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Macquarie Group's FATE Position: Q4 2022 in Review

Macquarie Group sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 636 shares — an estimated $40K sold.

Macquarie Group first reported a position in FATE in Q4 2017 and held it in 14 quarters. The position peaked at $6.83M in Q4 2020. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Macquarie Group reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Macquarie Group sold 636 Fate Therapeutics shares in Q4 2022, an estimated $40K.
  • Macquarie Group first reported a position in Fate Therapeutics in Q4 2017 and held it in 14 quarters.
  • Macquarie Group's Fate Therapeutics position peaked at $6.83M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.